These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 26396524

  • 1. New advances in the treatment of generalized lipodystrophy: role of metreleptin.
    Rodriguez AJ, Mastronardi CA, Paz-Filho GJ.
    Ther Clin Risk Manag; 2015; 11():1391-400. PubMed ID: 26396524
    [Abstract] [Full Text] [Related]

  • 2. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G, Akinci B.
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [Abstract] [Full Text] [Related]

  • 3. Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy.
    Simha V.
    Expert Rev Endocrinol Metab; 2014 May; 9(3):205-212. PubMed ID: 30736159
    [Abstract] [Full Text] [Related]

  • 4. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
    Tchang BG, Shukla AP, Aronne LJ.
    Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
    [Abstract] [Full Text] [Related]

  • 5. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
    Akinci B, Meral R, Rus D, Hench R, Neidert AH, DiPaola F, Westerhoff M, Taylor SI, Oral EA.
    Endocrinol Diabetes Metab Case Rep; 2020 Mar 25; 2020():. PubMed ID: 32213649
    [Abstract] [Full Text] [Related]

  • 6. Rationale for leptin-replacement therapy for severe lipodystrophy.
    Oral EA, Chan JL.
    Endocr Pract; 2010 Mar 25; 16(2):324-33. PubMed ID: 20061299
    [Abstract] [Full Text] [Related]

  • 7. Treatment Options for Lipodystrophy in Children.
    Mainieri F, Tagi VM, Chiarelli F.
    Front Endocrinol (Lausanne); 2022 Mar 25; 13():879979. PubMed ID: 35600578
    [Abstract] [Full Text] [Related]

  • 8. Leptin replacement therapy in the management of lipodystrophy syndromes.
    Vigouroux C, Mosbah H, Vatier C.
    Ann Endocrinol (Paris); 2024 Jun 25; 85(3):201-204. PubMed ID: 38871500
    [Abstract] [Full Text] [Related]

  • 9. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
    Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P.
    Expert Rev Clin Pharmacol; 2016 Jun 25; 9(1):59-68. PubMed ID: 26465174
    [Abstract] [Full Text] [Related]

  • 10. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1511-1519. PubMed ID: 28324110
    [Abstract] [Full Text] [Related]

  • 11. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P.
    Endocr Pract; 2011 May 01; 17(6):922-32. PubMed ID: 22068254
    [Abstract] [Full Text] [Related]

  • 12. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
    Nagayama A, Ashida K, Watanabe M, Moritaka K, Sonezaki A, Kitajima Y, Takahashi H, Yoshinobu S, Iwata S, Yasuda J, Hasuzawa N, Ozono S, Motomura S, Nomura M.
    Front Endocrinol (Lausanne); 2021 May 01; 12():690996. PubMed ID: 34135866
    [Abstract] [Full Text] [Related]

  • 13. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, Cai H, Gharib AM, Ouwerkerk R, Courville AB, Bernstein S, Brychta RJ, Chen KY, Walter M, Auh S, Gorden P.
    J Clin Invest; 2018 Aug 01; 128(8):3504-3516. PubMed ID: 29723161
    [Abstract] [Full Text] [Related]

  • 14. Metreleptin treatment of non-HIV lipodystrophy syndromes.
    Chevalier B, Lemaitre M, Leguier L, Mapihan KL, Douillard C, Jannin A, Espiard S, Vantyghem MC.
    Presse Med; 2021 Nov 01; 50(3):104070. PubMed ID: 34571177
    [Abstract] [Full Text] [Related]

  • 15. Effects of Metreleptin on Patient Outcomes and Quality of Life in Generalized and Partial Lipodystrophy.
    Cook K, Adamski K, Gomes A, Tuttle E, Kalden H, Cochran E, Brown RJ.
    J Endocr Soc; 2021 Apr 01; 5(4):bvab019. PubMed ID: 33817539
    [Abstract] [Full Text] [Related]

  • 16. Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report.
    Pedicelli S, de Palma L, Pelosini C, Cappa M.
    Ital J Pediatr; 2020 Oct 24; 46(1):158. PubMed ID: 33099310
    [Abstract] [Full Text] [Related]

  • 17. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
    Araujo-Vilar D, Sánchez-Iglesias S, Guillín-Amarelle C, Castro A, Lage M, Pazos M, Rial JM, Blasco J, Guillén-Navarro E, Domingo-Jiménez R, del Campo MR, González-Méndez B, Casanueva FF.
    Endocrine; 2015 May 24; 49(1):139-47. PubMed ID: 25367549
    [Abstract] [Full Text] [Related]

  • 18. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T, Cochran E, Gorden P, Brown RJ.
    J Clin Endocrinol Metab; 2015 May 24; 100(5):1802-10. PubMed ID: 25734254
    [Abstract] [Full Text] [Related]

  • 19. Update on Therapeutic Options in Lipodystrophy.
    Akinci B, Meral R, Oral EA.
    Curr Diab Rep; 2018 Oct 29; 18(12):139. PubMed ID: 30370487
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.
    Ajluni N, Dar M, Xu J, Neidert AH, Oral EA.
    J Diabetes Metab; 2016 Mar 29; 7(3):. PubMed ID: 27642538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.